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The aim of this study was to explore if estimates of renal function could explain variability of 123I-metaiodobenzylguanidine
(123I-MIBG) assessed myocardial sympathetic activity. Furthermore estimates of renal function were compared to 123I-MIBG as
predictors of cardiac death in chronic heart failure (CHF). Semi-quantitative parameters of 123I-MIBG myocardial uptake and
washout were calculated using early heart/mediastinum ratio (H/M), late H/M and washout. Renal function was calculated as
estimated Creatinine Clearance (e-CC) and as estimated Glomerular Filtration Rate (e-GFR). Thirty-nine patients with CHF (24
males;age:64.4±10.5years;NYHAII/III/IV:17/20/2;LVEF:24.0±11.5%)werestudied.Variabilityinanyofthesemi-quantitative
123I-MIBG myocardial parameters could not be explained by e-CC or e-GFR. During follow-up (60 ± 37 months) there were 6
cardiac deaths. Cox proportional hazard regression analysis showed that late H/M was the only independent predictor for cardiac
death (Chi-square 3.2, regression coeﬃcient: −4.095; standard error: 2.063; hazard ratio: 0.17 [95% CI: 0.000–0.950]). Addition
of estimates of renal function did not signiﬁcantly change the Chi-square of the model. Semi-quantitative 123I-MIBG myocardial
parameters are independent of estimates of renal function. In addition, cardiac sympathetic innervation assessed by 123I-MIBG
scintigraphy seems to be superior to renal function in the prediction of cardiac death in CHF patients.
1.Introduction
The myocardial sympathetic nervous system is activated
in patients with chronic heart failure (CHF) and has been
shown to be associated with increased mortality. Cardiac
sympathetic innervation can be scintigraphically visuali-zed
by 123I-metaiodobenzylguanidine (123I-MIBG), a radiola-
belled analog of noradrenalin and has been shown to be a
powerful prognostic marker in patients with CHF [1, 2].
In addition to 123I-MIBG there are many other progno-
stic markers in patients with CHF. Estimates of renal func-
tion, for example, as measured by creatinine clearance and
glomerular ﬁltration rate (GFR), have been associated with
mortality and morbidity in CHF [3–5]. Interestingly in
patients with chronic renal failure myocardial washout of
123I-MIBG, as a measure of increased myocardial sympa-
thetic activity, has been shown to be increased [6]. However,
there is limited data on a direct comparison of the respective
prognostic predictive value of sympathetic hyperactivity and
renaldysfunction[7].Majorclinicaltrialsaimedtoassessthe
prognostic value of 123I-MIBG have often excluded patients
with substantial renal failure, further limiting the amount of
prognostic information comparing these two variables [2].
Furthermore, there are complex interactions between
sympathetic regulation of renal function and cardiac func-
tion. For example increased sympathetic activity reduces the
renalﬁltrationfraction[8,9]andareducedGFRisassociated
with a reduced blood clearance of 123I-MIBG [10]. In a
recent study it was shown that diﬀerences in the rate of renal
excretion did not contribute to variability in the mediastinal
and myocardial 123I-MIBG uptake [11]. However, whether
this reduced blood clearance of 123I-MIBG has any impact
on the semiquantitative myocardial parameters is unknown.2 International Journal of Molecular Imaging
Therefore, the purpose of this study was twofold: (1) to
exploreifestimatesofrenalfunctioncouldexplainvariability
of 123I-MIBG assessed myocardial sympathetic activity and
(2) to compare the prognostic value of estimates of renal
function and myocardial 123I-MIBG assessed myocardial
sympathetic activity in patients with CHF.
2.MaterialandMethods
The study was designed to reevaluate the results of 123I-
MIBG imaging studies and renal function in patients with
CHF prior to 1 November, 2006 in relation to cardiac events.
Requirements for inclusion of subjects in this “retrospective”
study were availability of the original digital 123I-MIBG
image ﬁles; availability of serum creatinine measurements
within1monthbefore 123I-MIBGscintigraphy.BetweenJan-
uary 1, 1996 and October 31, 2006, 39 CHF patients visiting
the outpatient heart failure clinic met these requirements.
Renal function was estimated using the serum creatinine-
based Cockcroft-Gault equation (estimated Creatinine
Clearance: e-CC) and the abbreviated MDRD equation
(estimated Glomerular Filtration Rate: e-GFR) [12, 13].
Dutch national law does not require local ethics committee
approval for retrospective studies. The study complies with
the Declaration of Helsinki.
CHF severity was clinically evaluated according to the
New York Heart Association (NYHA) classiﬁcation at the
time of imaging. The census date for follow-up was set at
the 1 November, 2008 (at least 24 months follow-up). The
mean follow-up after 123I-MIBG scintigraphy was 60.1±37.2
months (range 1–149 months).
2.1. Measurement of Serum Creatinine. Serum concentra-
tions of creatinine were determined according to routine
hospital procedure. Reference levels for creatinine were 75–
110µmol/L for men and 65–95µmol/L for women, resp-
ectively.
2.2. Renal Function. Renal function was determined by e-CC





















×(1.04 for femals and 1.23 for males).
(1)
The e-GFR was calculated using the abbreviated MDRD
equation:











−0.203 ×[0.742 for females]
×[1.212 for blacks],
(2)
e-GFR was expressed per 1.73m2 of body surface area
(mL/min/1.73m2). According to the guidelines for identi-
ﬁcation, management and referral of adults with chronic
kidney disease, patients were stratiﬁed to an impaired kidney
function (e-CC or e-GFR <60mL/min(/1.73m2)) and those
with a normal e-CC or e-GFR (i.e., ≥60mL/min/1.73m2)
[14].
2.3. 123I-MIBG: Acquisition and Semiquantitative Analysis.
Patients underwent myocardial scintigraphy to determine
123I-MIBG uptake reﬂecting neural norepinephrine reuptake
andretention.Toblockthyroiduptakeoffree 123I,allpatients
received 100mg potassium iodide orally, one hour prior to
the injection of 123I-MIBG. After a subsequent resting period
of at least 30 minutes, patients were injected intravenously
with approximately 185MBq (5mCi) of 123I-MIBG (GE
Healthcare, Eindhoven, The Netherlands). Fifteen minutes
(early imaging) and 4h (delayed imaging) after MIBG
administration, a10-minplanar anteriorimageofthethorax
was acquired using a dual-head gamma-camera (e-cam,
Siemens, Hoﬀman Estate, Illinois, USA). A 20% energy
window was centred on the 159keV photon peak of 123I.
Images were acquired using a medium energy collimator and
stored in 128∗128 matrix [15].
An experienced nuclear medicine technologist processed
all planar images on a workstation (HERMES Medical Solu-
tions, Stockholm, Sweden). The analysis of the myocardial
scintigraphy data was performed blind to clinical status and
estimates of renal function. 123I-MIBG myocardial activity
was measured using a manually drawn region of interest
(ROI) around the LV. The positioning of the ﬁxed mediasti-
nal ROI was standardized in relation to the lung apex, the
lower boundary of the upper mediastinum, and the midline
between the lungs [16]. To evaluate 123I-MIBG myocardial
uptake, the Heart/Mediastinum (H/M) ratio was calculated
from the early (early H/M) and delayed images (late H/M).
Myocardial 123I-MIBG washout (WO) was deﬁned as the
percentage of change in activity from the early and delayed
images:






2.4. Follow-Up. Th ep ri m a ryo u t c o m ew a sd e ﬁ n eda sc a r d i ac
death during follow-up (aggregated from: death due to acute
pulmonary oedema, progressive heart failure, myocardial
infarction, or ventricular arrhythmia). The secondary out-
come was deﬁned as potentially lethal ventricular arrhyth-
mias during follow-up: documented episode of spontaneous
sustained ventricular tachycardia (>30s) ventricular tach-
yarrhythmia, resuscitated cardiac arrest, or appropriate ICD
discharge (antitachycardia pacing or deﬁbrillation). Long-
term follow-up data were obtained from at least one of
three sources: visit to the outpatient clinic; review of the
patient’s hospital records; personal communication with the
patient’s physician. An experienced cardiologist reviewed
source documents to conﬁrm occurrence of events. The
cardiologist was blinded for both the estimates of renal func-
tion and the 123I-MIBG scintigraphic data.
3. Statistics
Mean values were tested for diﬀerences using the unpaired t-
test. Linear regression was used to examine the relationship
between the estimates of renal function (e-CC and e-GFR)
and the 123I-MIBG scintigraphic data (i.e., early H/M, late
H/Mandwashout).TheoverallgoodnessofﬁtwasexpressedInternational Journal of Molecular Imaging 3
as the adjusted R2.T h eF-test was used to assess whether the
model explained a signiﬁcant proportion of the variability. A
signiﬁcant adjusted R2 would indicate that variation in the
scintigraphically determined parameters could be explained
by a percentage (adjusted R2) of change in estimates of renal
function. Multivariate Cox proportional hazard regression
analysis was used to investigate the relation between survival
and the following parameters: age, gender, several CHF
variables, estimates of renal function and the 123I-MIBG
scintigraphic data. First, several CHF variables (left ventric-
ular ejection fraction (LVEF), NYHA class, QRS duration)
and 123I-MIBGsemiquantitative myocardial parameters(i.e.,
early H/M, late H/M and myocardial washout) were entered
intothemodelaccordingastepwiseforwardlikelihoodratio-
based method. Secondly, the possible additional value of
renal function (e-CC and e-GFR) was determined. These
data were added to the ﬁrst model according the enter
method (forced addition to the model). Chi-square, Cox
proportional hazard regression coeﬃcient (coeﬃcient B),
and exponent (exponent B) were used to describe the model
and relative contribution of the parameters to the model.
Exponent B is the predicted change in hazard for a unit
increase in the predictor (i.e., hazard ratio). A P value <
0.05 was considered to indicate statistical signiﬁcance. All
statistical analyses were performed with SPSS (SPSS for
Windows, version 16.0, SPSS Inc, Chicago, Il, USA).
4. Results
Thirty-nine patients with CHF were included in this study;
all patients had stable CHF. Baseline characteristics are
described in Table 1. Twenty-three patients (59%) had ische-
mia-related CHF and sixteen patients had nonischemic
CHF. Patients with ischemia-related CHF had a lower LVEF
compared to those with nonischemic CHF (P = 0.034). The
majority was male (62%) with a mean age of 64.4 ± 10.5
years. At baseline 94.9% of patients were treated with loop
diuretics, 82.1% were on angiotensin converting enzyme
(ACE) inhibitor or angiotensin receptor blocker (ARB), and
46.2% were on beta-blockers.
4.1. 123I-MIBG and Estimates of Kidney Function. The mean
early H/M ratio was 1.61 ± 0.46, the mean late H/M was
1.43±0.38andthemeanwashoutwas10.1±10.4%(Table 2).
There was no diﬀerence in the 123I-MIBG semiquantitative
parameters or in the e-CC and e-GFR between ischemic and
nonischemic related CHF.
There were 17 patients with an impaired renal function
based on e-CC (39.5 ± 10.5mL/min, range 17–56mL/min)
a n d2 3w i t ha ni m p a i r e dr e n a lf u n c t i o nb a s e do ne - G F R
(42.0±11.3mL/min/1.73m2,range17–59mL/min/1.73m2).
Patients with a decreased e-CC or a decreased e-GFR did not
diﬀer in 123I-MIBG semiquantitative parameters compared
withpatientswithanormale-CCornormale-GFR(Table 3).
The variability in any of the 123I-MIBG semiquantitative
parameters could not be explained by either e-CC or e-
GFR (Table 4). Estimates of renal function could at best
explain approximately 3% of the variability of the 123I-MIBG
semiquantitative parameters (P = 0.851).
4.2. Cardiac Death. During follow-up 6 of the 39 (15.4%)
patients had a cardiac death; mean interval after 123I-MIBG
scintigraphy to cardiac death was 22 months with a range
from 4 to 54 months. All 6 patients died as a result of
severe progressive heart failure. Characteristics of patient
with cardiac death and survivors are described in Table 5.
The cardiac deaths were more likely to have a nonischemic
aetiologyofheartfailure(P = 0.022).Therewasastatistically
not signiﬁcant trend towards lower e-CC and e-GFR values
for patients with cardiac death compared to survivors (e-CC
53.4 ± 20.9v e r s u s6 7 .8 ± 34.5, P = 0.375; e-GFR 49.1 ± 15.7
versus 62.0 ±26.6, P = 0.259, resp.).
Cox proportional hazard regression analysis showed that
late H/M was the only independent predictor for cardiac
death (Chi-square 3.2, coeﬃcient B: −4.095; standard error:
2.063; hazard ratio: 0.17, 95% CI:0.000–0.950). Forced
addition of estimates of renal function did not signiﬁcantly
change the Chi-square of the model (Figure 1(a)).
4.3. Potentially Lethal Ventricular Arrhythmia. Nine patients
developed potentially lethal ventricular arrhythmia: 5 had
sustained ventricular tachycardia, 1 patient was resuscitated
from a cardiac arrest, and 3 patients had an appropriate
ICD discharge (i.e., antitachycardia pacing). None of these
arrhythmias resulted in sudden cardiac death.
Cox proportional hazard regression analysis showed that
QRS duration was the only independent predictor for a
potentially lethal ventricular arrhythmia (Chi-square 8.5,
coeﬃcient B: 0.028; standard error: 0.010; hazard ratio:
1.028, 95% CI:1.021–1.049). Forced addition of estimates
of renal function did not signiﬁcantly change the Chi-
square of the model (Figure 1(b)). None of the 123I-MIBG
semiquantitative parameters was predictive for a potentially
lethal ventricular arrhythmia.
5. Discussion
Semi-quantitative 123I-MIBG myocardial parameters are
independent of estimates of renal function. In addition,
cardiac sympathetic innervation assessed by 123I-MIBG
scintigraphy seems to be superior to renal function in the
prediction of prognosis in CHF patients.
5.1. Renal Function and 123I-MIBG. In subjects with a nor-
mal kidney function, intravenous administrated 123I-MIBG
is almost exclusively excreted via the kidneys within 24 hours
after injection with approximately 35% of administered 123I-
MIBG already excreted by 6 hours [17, 18]. As a reduced
GFR is associated with a reduced blood clearance of 123I-
MIBG, the excretion of 123I-MIBG is not only dependent on
ﬁltration but also by tubular secretion [10]. In short kidney
function is essential for the clearance of 123I-MIBG and
may therefore inﬂuence scintigraphic outcome. However,
the results of our study show that the variability in the
semiquantitative 123I-MIBG myocardial parameters cannot
be explained by estimates of renal function. Therefore within
the time frame of 123I-MIBG cardiac imaging (up to 4 hours
after injection), the semiquantitative 123I-MIBG myocardial4 International Journal of Molecular Imaging
Table 1: Patient characteristics.
Overall Ischemic Nonischemic P value
N = 39 N = 23 N = 16
Age (years) 64 ± 11 66 ± 10 61 ± 11 0.962
Female/Male 15/24 6/17 7/9 0.057
NYHA class 0.351
II 17 8 9
III 20 12 8
IV 2 2 0
Medical history
Myocardial infarction 21 21 0 <0.001
CABG 8 8 0 0.008
PCI 4 4 0 0.078
Hypertension 10 5 5 0.428
Diabetes Mellitus 9 5 4 0.727
Medication
Loop diuretics 37 22 8 0.791
ACE-I 29 17 12 0.939
ARB 3 2 1 0.778
Beta blockers 18 10 8 0.688
Amiodarone 13 9 4 0.357
Digoxin 9 4 5 0.312
Calcium channel blockers 3 2 1 0.778
LVEF (%) 24.0 ±11.52 0 .7 ±8.62 8 .6 ±13.6 0.034
ECG
QRS duration (msec) 163 ± 43 167 ± 36 158 ± 54 0.564
LBBB 32 21 11 0.116
RBBB 1 1 0 0.418
AF 4 2 2 0.700
NYHA class: New-York Heart association functional classiﬁcation of heart failure; CABG: coronary artery bypass graft; PCI: percutaneous coronary
intervention; ACE-I: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; LVEF: left ventricular ejection fraction; LBBB: left bundle
branch block; RBBB: right bundle branch block; AF: atrial ﬁbrillation.
Table 2: Estimates of renal function and 123I-MIBG results.
Overall Ischemic Nonischemic P value
Renal function N = 39 N = 23 N = 16
e-CC 65.7 ±33.15 8 .1 ±27.57 8 .6 ±38.6 0.076
e-GFR 60.0 ±25.55 5 .1 ±26.66 7 .1 ±22.7 0.153
123I-MIBG
Early H/M 1.61 ±0.46 1.51 ±0.32 1.75 ±0.58 0.108
Late H/M 1.43 ±0.38 1.36 ±0.26 1.54 ±0.49 0.139
Washout 10.1 ±10.49 .21 ±10.11 1 .4 ±11.0 0.528
e-CC: estimated Creatinine Clearance; e-GFR: estimated Glomerular Filtration Rate. See for other abbreviations Table 1.
parametersareindependentofrenalfunction.Theseﬁndings
are in line with a recent publication showing that diﬀerences
in the rate of renal excretion did not contribute to variability
mediastinal and myocardial between early and late planar
123I-MIBG images [11]. This is eminent for clinical practice
asrenaldysfunctionisoftenpresentinCHFpatients[19,20].
5.2. Renal Function, 123I-MIBG, and Prognosis in CHF. Renal
dysfunction is not often present in patients with CHF; the
serumcreatinine-basedestimatesofrenalfunctionhavebeen
shown to be independently related to mortality [21–25].
In addition the sympathetic nervous system is one of the
neurohormonal compensation mechanisms that plays an
important role in the pathogenesis of CHF. Activation of
this cardiac sympathetic system causes downregulation and
desensitization of cardiac beta-adrenoreceptors and modi-
ﬁcation in the postsynaptic signal transduction which con-
tributes to arrhythmia development, progression of heartInternational Journal of Molecular Imaging 5
Table 3: Normal versus abnormal estimates of kidney function in relation to 123I-MIBG.
e-CC <60mL/min ≥60mL/min P value
N = 17 N = 22
Early H/M 1.45 ±0.36 1.74 ±0.49 0.490
Late H/M 1.29 ±0.29 1.54 ±0.41 0.370
Washout 9.9 ±11.11 0 .3 ±10.0 0.915
e-GFR <60mL/min/1.73m2 ≥60mL/min/1.73m2
P value
N = 23 N = 16
Early H/M 1.57 ±0.42 1.67 ±0.51 0.492
Late H/M 1.38 ±0.39 1.51 ±0.36 0.309
Washout 11.2 ±12.28 .5 ±7.0 0.432
See for abbreviations Tables 1 and 2.
Table 4: Variability of the estimates of renal function in relation to 123I-MIBG scintigraphic parameters.
Constant Stand error c Coeﬃcient b Stand error b Adjusted R2 P value
e-CC versus early H/M 49.3 21.2 10.6 13.1 −0.011 0.428
e-CC versus late H/M 40.4 24.0 18.2 16.8 0.005 0.285
e-CC versus washout 66.8 8.0 −0.1 0.6 −0.029 0.851
e-GFR versus early H/M 59.1 15.4 0.6 9.2 −0.027 0.948
e-GFR versus late H/M 50.4 16.3 6.7 11.0 −0.017 0.546
e-GFR versus washout 64.8 5.7 −0.5 0.4 0.011 0.240
See for abbreviations Tables 1 and 2.
Table 5: Characteristics of cardiac deaths compared to survivors.
Cardiac death Survivor P value
N = 6 N = 33
Age (years) 64 ± 14 64 ± 10 0.990






Ischemic/nonischemic 1/5 22/11 0.022
LVEF (%) 20.8 ±10.92 4 .6 ±11.7 0.467
ECG
QRS duration (msec) 175 ± 66 161 ± 38 0.471
LBBB 5 27 0.647
Renal function
e-CC 53.4 ±20.96 7 .8 ±34.5 0.375
e-GFR 49.1 ±15.76 2 .0 ±26.6 0.259
123I-MIBG
Early H/M 1.57 ±0.36 1.62 ±0.47 0.839
Late H/M 1.34 ±0.30 1.45 ±0.39 0.512
Washout 14.2 ±12.79 .4 ±9.9 0.302























































Figure 1: (a) Model predicting cardiac death: late H/M enters the model ﬁrst (Chi-square  3.2). The addition of renal function did not
signiﬁcantly change the model (Chi-square for the model including e-CC  4.1 and for the model including e-GFR  4.0, resp.). (b) Model
predicting potentially lethal arrhythmia: QRS duration is the only signiﬁcant contributor to the model (Chi-square  8.5). The addition of
renal function did not signiﬁcantly change the model (Chi-square for the model including e-CC  8.7 and for the model including e-GFR 
9.1, resp.).
failure, and ultimately cardiac death. Our results conﬁrm
previous ﬁndings that increased cardiac sympathetic activity
assessed by 123I-MIBG scintigraphy is related to mortality
[1, 2, 26].
However, there is limited data on a direct comparison
of the respective prognostic predictive value of sympathetic
innervation and renal dysfunction. To our knowledge only
Furuhashi and Moroi studied this speciﬁc subject
[7]. In patients with CHF and a preserved GFR
(≥60mL/min/1.73m2) Cox proportional hazard regression
analysisshowedthatlateH/Mratiowastheonlyindependent
predictor of cardiac death. However, the study lacked sta-
tistical power to perform Cox proportional hazard regres-
sion analysis in the patient group with an impaired renal
function (GFR <60mL/min/1.73m2).
The lack of additional prognostic value of renal function
in our study might be explained by several diﬀerent but
probably interacting factors. First, the aetiology of CHF
diﬀers between diﬀerent studies. In studies with a larger
number of patients with ischemia-related cardiomyopathy,
a higher predictive value of renal function was found. This
might be explained by concomitant peripheral vascular dis-
ease and secondary nephrosclerosis. Our patient cohort was
notlargeenoughtoallowforadequatesubgroupanalysisand
therefore concomitant peripheral vascular disease remains
a theoretical explanation for the found discrepancies. Sec-
ondly, the diﬀerences between our results and the ﬁndings
of others may be related to the prevalence of reduced kidney
function. However, even in patients with increased serum
creatininelevels(>2.5mg/dLor>220µmol/L,approximately
3% of the study population), Opasich et al. were not able
to identify renal function as a prognostic indicator [27].
Approximately 47% of our study population had at least a
moderate impairment of renal function (i.e., e-CC or e-GFR
<60mL/min (/1.73m2)). This prevalence is slightly lower
compared to the majority of published data. Prevalence of
renal dysfunction does therefore not explain the absence of
renal function as a prognostic indicator.
6. LimitationsandClinicalImplications
The main limitation of this study is the small number of
patients collected over an extended period of time when
therapeutic guidelines were changing. This is reﬂected by
the fact that the majority of included patients is relatively
undertreated according to the current guidelines [28, 29].
Furthermore the mortality rate seems to be relatively low
(i.e., 15%). However, the mortality rate is in line with the
mortality rate as reported by other publications. Furuhashi
and Moroi reported a mortality rate of 11% during a mean
follow-up period of 33.7 months [7] and the cardiac mor-
tality rate of the ADMIRE-HF study (6% during a median
follow-up period of 17 months) [2]. The extrapolation of
the prognostic predictive value of our study is probably
inﬂuenced by these factors. The prognostic ﬁndings of
our study should therefore be considered as preliminary.
However, it remains that the aforementioned factors have
no impact on the ﬁnding that semiquantitative 123I-MIBG
myocardial parameters are independent of estimates of renal
function.
7. Conclusion
Semi-quantitative 123I-MIBG myocardial parameters are
independent of estimates of renal function. Although the
ﬁndings on the prognostic predictive value of this study
should be considered as preliminary, the observations sug-
gest that cardiac sympathetic innervation assessed by 123I-
MIBG scintigraphy is superior in the prediction of prognosis
in patients with CHF to estimates of renal (dys)function.
This ﬁnding might be clinically relevant as creatinine clear-
ance is less costly to assess than 123I-MIBG.
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